TRIAL DETAIL
Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 06/16/2007 |
Age of Trial (yrs) 17.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
XL147-001 |
|||
Sponsor: |
Exelixis |
|||
Patient Contact: |
Exelixis Contact Line |
|||
Contact email: |
||||
Contact Phone: |
866-939-4041 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. |
|||
Trial Links |
Trial Results |
Drug Information |
| Exelixis pipeline |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
119-129 |
Barcelona |
08035 |
Spain |
||
Dallas |
TX |
75246 |
USA |